IONS as reported
Ionis Pharmaceuticals, Inc. reported $874M of revenue over the trailing twelve months, −7.4% on the year before. 11 reported series are charted on this page, each one as filed.
$874M
Revenue, trailing twelve months · to Q2 2026 · −7.4% against the twelve months before
- Net Income
- −$565M
Net Income · +111% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$561M
Free Cash Flow · +93% year on year · trailing twelve months to Q2 2026
- Op Margin
- −73%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $874M | −7.4% | Q2 2026 |
| Net Income | −$565M | +111% | Q2 2026 |
| EPS | −$3.46 | +88% | Q2 2026 |
| Gross Margin | 98% | n/a | Q2 2026 |
| Op Margin | −73% | n/a | Q2 2026 |
| Net Margin | −69% | n/a | Q2 2026 |
| ROE | −79% | n/a | Q2 2026 |
| ROA | −12% | n/a | Q2 2026 |
| ROIC | −36% | n/a | Q4 2019 · 26 quarters behind |
| Free Cash Flow | −$561M | +93% | Q2 2026 |
| P/E | 50.7 | n/a | Q3 2020 · 23 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ionis Pharmaceuticals, Inc. (IONS) - Revenue & ProfitRevenue & ProfitIonis Pharmaceuticals, Inc. (IONS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com